Business
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer - - Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab
About this update from Alx Oncology Holdings Inc.
[{"type":"image","alt":"ALX Oncology","displaySize":"","headline":null,"caption":"ALX Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":195,"url":"https://media.zenfs.com/en/globenewswire.com/470f956a3deddaf81b04c64bb1806e3d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8NbmnYnY6PonTEovaMtfQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Mw--/https://media.zenfs.com/en/globenewswire.com/470f956a3deddaf81b04c64bb1806e3d","width":300,"height":195},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/8NbmnYnY6PonTEovaMtfQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Mw--/https://media.zenfs.com/en/globenewswire.com/470f956a3deddaf81b04c64bb1806e3d","width":300,"height":195}},"lazy":false},{"type":"text","content":"- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -","length":227,"tagName":"p"},{"type":"text","content":"- Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer -","length":185,"tagName":"p"},{"type":"text","content":"- Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 -","length":184,"tagName":"p"},{"type":"text","content":"- Phase 1 trial evaluating ALX2004 continues to enroll well, on track for safety data in 2H 2026 -","length":98,"tagName":"p"},{"type":"text","content":"- ALX strengthens leadership team with the appointment of Jeff Knight as Chief Development and Operating Officer -","length":114,"tagName":"p"},{"type":"text","content":"- Company to host webcast including presentation of ESMO Breast data by breast cancer expert Sara Hurvitz, M.D., FACP, on Friday, May 8, at 5:30 a.m. PT / 8:30 a.m. ET -","length":170,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today reported financial results for the first quarter ended March 31, 20...